These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33596357)

  • 1. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
    N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
    Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
    Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
    Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    Obstet Gynecol; 2022 Dec; 140(6):920-930. PubMed ID: 36357960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
    Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
    Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY
    Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
    Al-Hendy A; Lukes AS; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    J Comp Eff Res; 2023 Aug; 12(8):e230069. PubMed ID: 37477173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.
    Venturella R; Rechberger T; Zatik J; Wagman RB; Zhu E; Rakov VG; Petraglia F
    Gynecol Endocrinol; 2023 Aug; 39(1):2249107. PubMed ID: 37634528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HO; Li Y; McKain L; Arjona Ferreira JC; Langenberg AG; Wagman RB; Stewart EA
    Pain Manag; 2023 Apr; 13(4):205-211. PubMed ID: 37183454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myfembree for fibroid-associated heavy menstrual bleeding.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):121-123. PubMed ID: 34550666
    [No Abstract]   [Full Text] [Related]  

  • 14. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
    Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
    N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
    Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
    Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
    Osuga Y; Enya K; Kudou K; Hoshiai H
    Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
    Muhammad J; Yusof Y; Ahmad I; Norhayati MN
    BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
    Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
    Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.